Themis Medicare Board of Directors
Get the latest insights into the leadership at Themis Medicare. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Nagraj Mogaveera | Interim Company Secretary, Compliance Officer & KMP |
| Dinesh S Patel | Chairman |
| Sachin D Patel | Managing Director & CEO |
| Adam Demeter | Non Independent & Non Executive Director, Representative of Foreign Collaborator |
| Rajneesh Anand | Non Independent & Non Executive Director |
| Bhaskar V Iyer | Non Executive Independent Director |
| Shishir Dalal | Non Executive Independent Director |
| Neha Thakore | Non Executive Independent Director |
| Nikunt Raval | Non Executive Independent Director |
| Reena S Patel | Alternate Director |
Themis Medicare FAQs
The board at Themis Medicare consists of experienced professionals, including Nagraj Mogaveera, Dinesh S Patel, and others, overseeing the company’s strategic and corporate governance.
Directors at Themis Medicare are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Nagraj Mogaveera is the current chairman at Themis Medicare.
Executive directors at Themis Medicare are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Themis Medicare adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Themis Medicare, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.
